Author

A. A. Fitzgerald

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

E. J. Fertig· 2 shared L. M. Weiner· 2 shared A. Nasir· 1 shared E. F. Davis-Marcisak· 1 shared E. F. Marcisak· 1 shared E. Glasgow· 1 shared E. M. Jaffee· 1 shared E. M. Mace· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. J. Fertig

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Fibroblast activation protein regulates natural killer cell migration, extravasation and tumor infiltration

A. A. Fitzgerald, R. E. Maynard, E. F. Marcisak, A. Nasir, E. Glasgow, S. Jablonski, P. Van der Veken, G. Pearson, S. E. Eisman, E. M. Mace, E. J. Fertig, L. M. Weiner

This study shows that fibroblast activation protein (FAP) is expressed by human NK cells and promotes their migration, extravasation, and tumor infiltration, suggesting FAP as a target to enhance NK cell-based therapies.

bioRxiv · Feb 3, 2021 · PreprintImmunology

Transfer learning between preclinical models and human tumors identifies conserved NK cell activation signature in anti-CTLA-4 responsive tumors

E. F. Davis-Marcisak, A. A. Fitzgerald, M. D. Kessler, L. Danilova, E. M. Jaffee, N. Zaidi, L. M. Weiner, E. J. Fertig

The paper uses transfer learning to identify a conserved NK cell activation signature in anti-CTLA-4 responsive tumors across preclinical models and humans, showing its clinical relevance.

bioRxiv · May 31, 2020 · PreprintCancer Biology